Observation on short-term efficacy of camrelizumab combined with chemotherapy in the treatment of advanced esophageal squamous cell carcinoma
Objective To analyze the impact of camrelizumab combined with chemotherapy on short-term efficacy of patients with advanced esophageal squamous cell carcinoma(ESCC).Methods 68 patients with advanced esophageal squamous cell carcinoma were randomly divided into a control group(35 cases)and an observation group(33 cases).The control group was treated with chemotherapy alone,and the observation group was treated with camrelizumab on the basis of chemotherapy.Patients in both groups were compared in terms of clinical efficacy,occurrence of adverse reactions and serum tumor markers[carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag),cytokeratin fragment antigen 21-1(CYFRA21-1)]before and after treatment.Results After treatment,the objective remission rate(ORR)and disease control rate(DCR)in the observation group were 60.61%and 81.82%,which were significantly higher than 34.29%and 51.43%in the control group(P<0.05).After treatment,the levels of CEA,SCC-Ag and CYFRA21-1 in both groups were significantly decreased compared with those before treatment,and the magnitude of decrease in the observation group was more significant than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Camrelizumab combined with chemotherapy for the treatment of patients with advanced esophageal squamous cell carcinoma can significantly reduce the levels of relevant tumor markers of patients,alleviate the clinical symptoms,improve the therapeutic effect,and no obvious adverse reactions have been seen,which is worthy of clinical recommendation and use.
NETL
NSTL
万方数据
